

ORAL COMMUNICATION

Highlighting the diversity of people living with HIV

OC 66 Socio-demographic, clinical and therapeutic features of persons with HIV (PWH) currently in care in Italy: data from the ICONA cohort

Authors

A. d'Arminio Monforte¹, A. Rodano¹, I. Fanti¹, C.F. Perno², D. Segala³, A. Santoro⁴, M.B. Pasticci⁵, L. Calza⁶, A. Carraro⁷, A. Cingolani⁸, M. Puoti⁹, A. Castagna¹⁰, S. Lo Caputo¹¹, A. Tavelli¹, A. Antinori¹² on behalf of Icona Foundation Study Group

Affiliation

¹ICONA Foundation, Milan, Italy, ²IRCCS Bambino Gesù Pediatric Hospital, Rome, Italy, ³Pathology Department, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy, ⁴Clinica di Malattie Infettive, ASST Santi Paolo e Carlo-Presidio Ospedaliero San Paolo, Milano, Italy, ⁵Infectious Diseases Unit, Santa Maria Terni Hospital, Terni, Italy, ⁶Infectious Diseases Unit, IRCCS Policlinico di Sant'Orsola, University of Bologna, Bologna, Italy, ⁷Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, ⁸Clinic of Infectious Diseases, Catholic University, Rome, Italy, ⁹Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ¹⁰Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, ¹¹Clinic of Infectious Diseases, Department of Clinical and Surgical Sciences, University of Foggia, Foggia, Italy, ¹²National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Roma, Italy

ABSTRACT

Background: Aim of this study is to characterize socio-demographic, clinical and therapeutic features of PWH currently in care in 61 Italian Infectious Diseases centers belonging to the ICONA cohort.

Material and Methods: All the PWH enrolled in ICONA with at >= follow-up in 2022-2023 are included. Data from the ICONA database including age, sex, nation of birth, scholarity, employment, mode of HIV transmission, last CD4 and HIV-RNA, ongoing ART line and regimens, and comorbidities are analyzed. In case of multiple visits only the more recent one is considered.

Results: A total of 10900 PWH are included; 2173 (19.9%) are females, median age is ¬49 years (IQR: 40-58), 1962 (18.0%) are > 60 years old, 2072 (19.0%) are born outside Italy. Sexual contacts are the most frequent mode of HIV transmission: 4947 (45.3%) by MSM, 4334 (39.7%) by heterosexual route. Median time from HIV diagnosis is 8.4 years (IQR: 3.9-13.9); 1531/10900 (14%) PWH have an AIDS diagnosis.

Current data on scholarity and employment are reported among the 1622 PWH enrolled in 2022-23: 154 (9.7%) have university degree, 32 (2%) have primary school degree. 54.2% PWH have a stable employment, 12,5% are unemployed.

A total of 190 (11.7% of the 1622 enrolled in 2022-23) are current recent (within one year) seroconverters.

A total of 541 (5.0%) have CD4<200 cells/mL, 1381 (12.7%) < 350/mL, 8112 (75.5%) >500cells/mL. Median CD4 is 722 cells/mL. HIV-RNA is <50 copies/mL in 9601 (89.2%), <200 copies/mL in 10006 (91.8%), >100,000 copies/mL in 311 (2.8%).

276 (2.5%) are affected by cardiovascular disease, 70 (0.6%) by non AIDS malignancies.

Total cholesterol >200/ml is reported in 3237 (29.6%), and triglicerydes>200/ml in 1167 (10.7%).

As refers to antiretroviral therapy (ART), 149 (1.3%) are naives, 2800 (25.7%) are at their first regimen, 2291 (21.0%) at 2nd and 5660 (51.9%) at ≥ 3 rd one (TABLE 1a and b).

Considering all lines of ART, BIC/FTC/TAF is the more frequent regimen (in 28.4% of 10751 on ART, 3TC/DTG the second one (22.7%), 471 (4.4%) are on treatment with Long-Acting agents. (Figure 1).

Conclusions: PWH currently in care in Italy are mostly men, aged 60 or older in one fifth of cases,

born outside of Italy in another fifth. The majority are at their third or more line of therapy. 3-drug INSTI based regimen are given in a large majority, and dual regimen are the second more used one. More than 90% are not sexually transmitters as HIVRNA is below 200 copies/mL; their immunologic condition is in normal range in two third of them. We may conclude that HIV is becoming a chronic long-lasting non infective illness in those who are in care. Still 12% of new enrolments acquired HIV infection less than one year before. These data demonstrate that there are still individuals who get infected now, either by subjects unknown to be HIV positive or by those missing care and/or therapy.

Demographic characteristics of 10,900 PWH in follow-up in 2022-2023			
	n	%	
Gender F	2173	19.9	
Italians	8828	80.9	
Non-italians	2072	19	
Risk Factor:			
Heterosexual contacts	4334	39.7	
Homo/Bisexual contacts	4947	45.3	
IDU/ex IDU	685	6.2	
Other/Unknown	934	8.5	
Age:			
18-30	697	6.3	
31-40	2204	20.2	
41-50	2942	26.9	
51-60	3095	28.3	
>60	1962	18	
Median age	49 (40-58	1	
Median BMI	24,5		
Educational level:			
Primary	32	2	
Intermediate	170	10.8	
High school	339	21.5	
University	154	9.7	
N/A	879	55.8	
Professional condition:			
Disabled	4	0.2	
Employee	644	40.9	
Housewife	19	1.2	
Occasional work	24	1.5	
Retired	56	3.5	
Self-employment	210	13.3	
Student	44	2.7	
Unemployed	198	12.5	
Other professional condition	28	1.7	
Unknown	347	22	

Demographic characteristics of 10,900 PWH in follow-up in 2022-2023			
	n	%	
CD4 strata:			
<200	541	5	
200-350	840	7.8	
351-500	1246	11.6	
>=500	8112	75.5	
Median CD4 (cell/μL)	722 (506-964)		
VL strata:			
<=50	9601	89.2	
50-200	405	3.7	
200-1000	130	1.2	
1000-10k	110	1	
10k-100k	202	1.8	
>100k	311	2.8	
Median VL	19 (1-20)		
AIDS	1531	14	
Comorbidity type:			
Cardiovascular	276	2.5	
Non AIDS defining	1309	12	
Non AIDS malignancies	70	0.6	
Triglycerides >200	1167	10.7	
Cholesterol >200	3237	29.6	
ARV line:			
1	2800	25.6	
2	2291	21	
>=3	5660	51.9	
Naïve	149	1.3	
Median duration of HIV (years)	8.4 (3.9-13.9)		

Table 1b

On going regimens (untill 3%) in PWH on ART (n=10751) in 2022-2023

FTC,TDF,DTG n=328

RPV,DTG N=377

3.5%

3TC,ABC,DTG n=442

4.1%

RPV,CAB n=471

3TC,TDF,DOR n=477

4.4%

FTC,TAF,RPV n=1055

3TC,DTG n=2445

FTC,TAF,RPV n=1055

3TC,DTG n=2445

FTC,TAF,BIC n=3056

0% 5% 10% 15% 20% 25% 30%

Figure 1

Table 1a